Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    7 0 0 0

Archives de pédiatrie
Volume 25, n° 3
pages 229-235 (avril 2018)
Doi : 10.1016/j.arcped.2018.01.002
Received : 16 Mars 2017 ;  accepted : 28 January 2018
Review Articles

Tout ce que vous devez connaître sur le méthylphénidate (sans oser le demander…)
All you need to know about methylphenidate (and dared not ask)

L. Zimmer a, b, c, d, P. Fourneret a, b, e,
a Hospices civils de Lyon, groupement hospitalier Est, Lyon, 69677 Bron cedex, France 
b Université Claude-Bernard-Lyon 1, université de Lyon, Lyon, France 
c Centre de recherche en neurosciences de Lyon, CNRS UMR 5292, Inserm U1028, 69677 Bron, France 
d CERMEP-imagerie du vivant, 69677 Bron, France 
e Laboratoire L2C2, CNRS UMR 5304, 69677 Bron, France 

Auteur correspondant. Service psychopathologie du développement, hôpital femme-mère-enfant, groupement hospitalier est, hospices civils de Lyon, 59, boulevard Pinel, 69677 Bron cedex, France.Service psychopathologie du développement, hôpital femme-mère-enfant, groupement hospitalier est, hospices civils de Lyon, 59, boulevard Pinel, 69677 Bron cedex, France.

Methylphenidate (MPH) remains the only accessible psychostimulant used in France in the attention and behavior disturbances of attention deficit disorder with or without hyperactivity (ADHD). Its prescription has been extended during the past decade to other neurodevelopmental disorders in children and adolescents, also associated with a deficit of attentional resources or, more broadly, fragility of executive functions. Despite its efficiency, validated by more than 400 randomized controlled and double-blind studies, and the good tolerance of MPH in these indications, this treatment remains limited in France because of many fears and other prejudices on the part of medical practitioners and/or families. This article, resulting from the complementary viewpoints of a psychiatrist and a neuropharmacologist, is not intended to advocate MPH but to present, in a concise and nuanced manner, the approved scientific data justifying and framing this prescription.

The full text of this article is available in PDF format.

Keywords : Methylphenidate, Attention deficit disorder, Executive functions, Pathophysiology, Neurodevelopmental disorders, Comorbidities

© 2018  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline